Table 1.
Characteristics of included prevalence studies.
| First author | Country | Published time | Type of study | Number of patients with COVID-19 | Number of COVID-19 patients with HIV | Mean age | Male/female | Diagnostic method |
|---|---|---|---|---|---|---|---|---|
| Kumar et al. (2020) | USA | 2020 | Case series | 50 | 1 | 50 | M | Real-time PCR |
| Calza et al. (2020) | Italy | 2020 | Case series | 756 | 26 | 53.8 | 19M/7F | Real-time PCR, blood tests, CD4 count |
| Collins et al. (2020) | USA | 2020 | Case series | 530 | 20 | 57 | 13M/6F/1TSF | NR |
| Emami et al. (2020) | Iran | 2020 | Case series | 1239 | 5 | NR | NR | Molecular tests, HRCT |
| Huang et al. (2020) | China | 2020 | Case series | 2804 | 17 | NR | NR | serology, Real-time PCR |
| Inciarte et al. (2020) | Spain | 2020 | Case series | 5683 | 53 | 44 | 8F/45M | ELISA, Real time PCR |
| Kirenga et al. (2020) | Uganda | 2020 | Case series | 56 | 4 | NR | NR | Real-time PCR, CXR |
| Mondi et al. (2020) | Italy | 2020 | Case series | 604 | 5 | 49.6 | 4M/1TSF | Real-time PCR, serology, radiology imaging |
| Shalev et al. (2020) | USA | 2020 | Case series | 2159 | 31 | 60.7 | 24M/7F | Real-time PCR, CT scan, CXR, blood tests, HIV VL |
| Blanco et al. (2020) | Spain | 2020 | Case series | 543 | 5 | 37.8 | 3M/2TSF | Real-time PCR, CXR, blood tests, CD4+ count |
TSF; Trans Female, PCR; Polymerase Chain Reaction, HRCT; High-resolution computed tomography, VL; Viral Load, CXR; Chest X-Ray, ELISA; Enzyme-Linked Immunosorbent Assay, NR; not report.